Last reviewed · How we verify
CBT-001
CBT-001 is a therapeutic candidate in development by Cloudbreak Therapeutics, but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | CBT-001 |
|---|---|
| Sponsor | Cloudbreak Therapeutics, LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or company disclosures, the precise molecular target and mechanism cannot be reliably determined. As a Phase 3 asset, CBT-001 has progressed through early development, but mechanism details remain proprietary or unavailable in public sources.
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium (PHASE3)
- Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBT-001 CI brief — competitive landscape report
- CBT-001 updates RSS · CI watch RSS
- Cloudbreak Therapeutics, LLC portfolio CI